Moving RNA out of discovery
and into diagnostics

“RNA-based diagnostics have the potential to significantly improve patient stratification, which is at the
heart of precision medicine.  It allows us to move beyond the predictive power of DNA, and into true
biomarker expression.  Treatment that provides the right drug for the right patient at the right time?
This will help us get there.”

Dr. Natalie LaFranzo

Director of Scientific Projects and Market Development

Pinnacle: The RNA-based biomarker
panel for cancer

Version: Beta

Cofactor Pinnacle enables the identification of important cancer associated features, not detectable by DNA sequencing alone.

 

Pinnacle measures the RNA expression of 318 prominent cancer genes, identifies those with oncogenic expression, and enables fusion identification in 283 critical cancer associated genes from any type of formalin-fixed or fresh frozen solid tumor.

pinnacle
Stay up to date with the latest on Cofactor Pinnacle.
paragon

Paragon: Profiling micro-
environment cell report for
Immuno-oncology

Version: Beta

Cofactor Paragon reports on the cellular components of the tumor micro-environment. 32 cell types are reported and provide valuable insight in studies aimed at understanding how the micro-environment and the immune activity plays a key role in efficacy of treatment.
Don’t miss key developments in Cofactor’s Immuno-Oncology assay.

Are you a translational researcher looking for a more flexible CAP/CLIA product?  Contact us to learn more about our RNA-seqDx offering.

CAP/CLIA-Grade RNA Sequencing Products

Product NameCatalog NumberDescriptionPrice per Sample
RNA-seqDxCFGDX-101CFGDx-102Fresh-Frozen CAP/CLIA RNA sequencing, 30 million single-end readsFresh-Frozen CAP/CLIA RNA sequencing, 60 million single-end reads$1000$1500

RNA-seqDx accepts RNA from fresh-frozen human samples only. Samples must meet minimum quality and quantity requirements for CAP/CLIA sequencing. QC Results provided within 72 hours. Please contact us to discuss other experimental designs for this protocol.  All offerings above include single-end 75 bp sequencing and delivery of raw FASTQ files only. This protocol does not include comparative expression analysis.  Minimum sample number 10; turnaround time dependent on batch size. Average turnaround time is 6 weeks for batch size of 24. 

Learn more about our other offerings.

Start typing and press Enter to search